{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-26-000007","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.386605+00:00","generated_at":"2026-05-15T11:18:46.905643+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M","bullets":["Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.","Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.","Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.","Signed five new programs during transition, including two commercial site transfer programs in Q4.","Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-26-000007","json":"https://secwatch.observer/filing/0001005286-26-000007.json","markdown":"https://secwatch.observer/filing/0001005286-26-000007.md","text":"https://secwatch.observer/filing/0001005286-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/0001005286-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/lndc-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:18:46.905643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}